These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22352814)

  • 1. CpG still rocks! Update on an accidental drug.
    Krieg AM
    Nucleic Acid Ther; 2012 Apr; 22(2):77-89. PubMed ID: 22352814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies.
    Hanagata N
    Int J Nanomedicine; 2017; 12():515-531. PubMed ID: 28144136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
    Weiner GJ
    J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
    Vollmer J; Krieg AM
    Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
    Klinman DM; Klaschik S; Sato T; Tross D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG motifs as possible adjuvants for the treatment of allergic diseases.
    Bohle B
    Int Arch Allergy Immunol; 2002 Nov; 129(3):198-203. PubMed ID: 12444316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of Toll-like receptor 9 activation.
    Krieg AM
    Nat Rev Drug Discov; 2006 Jun; 5(6):471-84. PubMed ID: 16763660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG DNA as a vaccine adjuvant.
    Bode C; Zhao G; Steinhagen F; Kinjo T; Klinman DM
    Expert Rev Vaccines; 2011 Apr; 10(4):499-511. PubMed ID: 21506647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of toll-like receptor therapeutics.
    Parkinson T
    Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiinfective applications of toll-like receptor 9 agonists.
    Krieg AM
    Proc Am Thorac Soc; 2007 Jul; 4(3):289-94. PubMed ID: 17607015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
    Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
    Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
    Zimmermann S; Dalpke A; Heeg K
    Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG oligodeoxynucleotides with double stem-loops show strong immunostimulatory activity.
    Yang L; Wu X; Wan M; Yu Y; Yu Y; Wang L
    Int Immunopharmacol; 2013 Jan; 15(1):89-96. PubMed ID: 23142503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technology evaluation: CpG-7909, Coley.
    Paul S
    Curr Opin Mol Ther; 2003 Oct; 5(5):553-9. PubMed ID: 14601526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumor effect of CpG oligonucleotides on human neuroblastoma xenografts in nude mice].
    Yao QH; Tang YJ; Gao FH; Tang JY
    Ai Zheng; 2009 Apr; 28(4):344-9. PubMed ID: 19622291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity.
    Gungor B; Yagci FC; Tincer G; Bayyurt B; Alpdundar E; Yildiz S; Ozcan M; Gursel I; Gursel M
    Sci Transl Med; 2014 May; 6(235):235ra61. PubMed ID: 24807558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
    Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
    J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice.
    Akiba H; Satoh M; Iwatsuki K; Kaiserlian D; Nicolas JF; Kaneko F
    J Invest Dermatol; 2004 Sep; 123(3):488-93. PubMed ID: 15304088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.